A recent court ruling could put a damper on licensing.
A portfolio licensing agreement between bio-tech companies MedImmune and Genentech was going well--that is, until it went bad.
When MedImmune took a patent dispute with Genentech to court, Genentech argued that MedImmune didn't have any legal footing to do so since it hadn't terminated its patent license. A lower court sided with Genentech, but the Supreme Court ruled that MedImmune didn't have to breach or terminate its patent license to take its complaint before a judge.
Continue Reading With an Entrepreneur Subscription Now 40% Off—Use Code SAVE40
Become a member to get unlimited access and support the voices you want to hear more from. Subscribe to Entrepreneur for just $49/year $29/year.
Not ready for an annual subscription?
Get 3 months free with code
Presented by zendesk